Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.52 |
| ▸ | CYTH3 | O43739 | 1/20 | 0.52 |
| ▸ | AKT1 | P31749 | 1/20 | 0.52 |
| ▸ | NAMPT | P43490 | 1/20 | 0.51 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29274465 | 0.82 | NAMPT (0.60) | NAMPTLMNAKMT2AALDH1A1POLB | |
| SCHEMBL9360223 | 0.81 | PDPK1 (0.61) | PDPK1CYTH3AKT1GPR35LMNA | |
| SCHEMBL9360691 | 0.80 | PDPK1 (0.56) | PDPK1CYTH3AKT1GPR35KMT2A | |
| SCHEMBL9359744 | 0.79 | PDPK1 (0.53) | PDPK1CYTH3AKT1GPR35LMNA | |
| SCHEMBL20265727 | 0.77 | PDPK1 (0.54) | PDPK1CYTH3AKT1GPR35LMNA | |
| SCHEMBL11867406 | 0.77 | PDPK1 (0.54) | PDPK1CYTH3AKT1GPR35LMNA | |
| SCHEMBL14741970 | 0.77 | KMT2A (0.50) | GPR35LMNATSHRKMT2AMEN1 | |
| SCHEMBL9762934 | 0.76 | PDPK1 (0.53) | PDPK1CYTH3AKT1GPR35KMT2A | |
| SCHEMBL9762855 | 0.76 | MAPT (0.53) | PDPK1CYTH3AKT1GPR35LMNA | |
| SCHEMBL4800113 | 0.74 | GPR35 (0.59) | PDPK1CYTH3AKT1GPR35LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3831383-A1 | BROMODOMAIN INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2021-06-09 | — | — | EP | disclosed |
| EP-3831383-A1 | BROMODOMAIN INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2021-06-09 | — | — | EP | disclosed |
| EP-3283077-B1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2021-03-10 | — | — | EP | disclosed |
| EP-3283077-B1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2021-03-10 | — | — | EP | disclosed |
| US-10807982-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-10807982-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-20200071332-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-03-05 | — | — | US | disclosed |
| US-20200071332-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-03-05 | — | — | US | disclosed |
| US-20180134710-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-05-17 | — | — | US | disclosed |
| US-20180134710-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-05-17 | — | — | US | disclosed |
| US-20180134710-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-05-17 | — | — | US | disclosed |
| US-9908885-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-03-06 | — | — | US | disclosed |
| US-9908885-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-03-06 | — | — | US | disclosed |
| US-9908885-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-03-06 | — | — | US | disclosed |
| EP-3283077-A2 | BROMODOMAIN INHIBITOR | Celgene Quanticel Research, Inc. (US) | 2018-02-21 | — | — | EP | disclosed |
| US-20170050968-A1 | BROMODOMAIN INHIBITOR | CELGENE QUANTICEL RESEARCH, INC. | 2017-02-23 | — | — | US | disclosed |
| US-20170050968-A1 | BROMODOMAIN INHIBITOR | CELGENE QUANTICEL RESEARCH, INC. | 2017-02-23 | — | — | US | disclosed |
| US-20170050968-A1 | BROMODOMAIN INHIBITOR | CELGENE QUANTICEL RESEARCH, INC. | 2017-02-23 | — | — | US | disclosed |
| WO-2016168682-A2 | BROMODOMAIN INHIBITOR | CELGENE QUANTICEL RESEARCH, INC. (US) | 2016-10-20 | — | — | WO | disclosed |
| WO-2016168682-A2 | BROMODOMAIN INHIBITOR | CELGENE QUANTICEL RESEARCH, INC. (US) | 2016-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071332-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | PDPK1 1376/4885CYTH3 1020/4885AKT1 1229/4885 |
| US-20170050968-A1 | BROMODOMAIN INHIBITOR | BRD3, BRPF3, EP300 | PDPK1 1384/4885CYTH3 988/4885AKT1 1220/4885 |
| US-10807982-B2 | Bromodomain inhibitors | BRD3, EP300, BRPF3 | PDPK1 1376/4885CYTH3 1020/4885AKT1 1229/4885 |
| US-20180134710-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | PDPK1 1376/4885CYTH3 1020/4885AKT1 1229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.